心脏结节病:何时及如何治疗炎症。

IF 4.2 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiac Failure Review Pub Date : 2021-11-22 eCollection Date: 2021-03-01 DOI:10.15420/cfr.2021.16
Gerard T Giblin, Laura Murphy, Garrick C Stewart, Akshay S Desai, Marcelo F Di Carli, Ron Blankstein, Michael M Givertz, Usha B Tedrow, William H Sauer, Gary M Hunninghake, Paul F Dellaripa, Sanjay Divakaran, Neal K Lakdawala
{"title":"心脏结节病:何时及如何治疗炎症。","authors":"Gerard T Giblin,&nbsp;Laura Murphy,&nbsp;Garrick C Stewart,&nbsp;Akshay S Desai,&nbsp;Marcelo F Di Carli,&nbsp;Ron Blankstein,&nbsp;Michael M Givertz,&nbsp;Usha B Tedrow,&nbsp;William H Sauer,&nbsp;Gary M Hunninghake,&nbsp;Paul F Dellaripa,&nbsp;Sanjay Divakaran,&nbsp;Neal K Lakdawala","doi":"10.15420/cfr.2021.16","DOIUrl":null,"url":null,"abstract":"<p><p>Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e17"},"PeriodicalIF":4.2000,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e7/cfr-07-e17.PMC8674699.pdf","citationCount":"17","resultStr":"{\"title\":\"Cardiac Sarcoidosis: When and How to Treat Inflammation.\",\"authors\":\"Gerard T Giblin,&nbsp;Laura Murphy,&nbsp;Garrick C Stewart,&nbsp;Akshay S Desai,&nbsp;Marcelo F Di Carli,&nbsp;Ron Blankstein,&nbsp;Michael M Givertz,&nbsp;Usha B Tedrow,&nbsp;William H Sauer,&nbsp;Gary M Hunninghake,&nbsp;Paul F Dellaripa,&nbsp;Sanjay Divakaran,&nbsp;Neal K Lakdawala\",\"doi\":\"10.15420/cfr.2021.16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.</p>\",\"PeriodicalId\":33741,\"journal\":{\"name\":\"Cardiac Failure Review\",\"volume\":\"7 \",\"pages\":\"e17\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2021-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e7/cfr-07-e17.PMC8674699.pdf\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiac Failure Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/cfr.2021.16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac Failure Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/cfr.2021.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 17

摘要

结节病是一种复杂的、多系统的炎症性疾病,具有异质的临床谱。大约25%的系统性结节病患者会累及心脏,这预示着预后较差。诊断,特别是孤立性心脏结节病,可能具有挑战性。缺乏随机数据存在于谁,何时以及如何治疗心肌结节病的心肌炎症。尽管如此,皮质类固醇仍然是炎症期治疗的主要药物,类固醇保护和生物制剂的作用也在不断发展。本文综述了结节病炎症的免疫发病机制、目前循证治疗指征和常用免疫抑制剂。它探索了心肌炎症的多学科治疗和监测方法,并概述了我们对这种情况的理解,新兴研究和未来方向的当前差距。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cardiac Sarcoidosis: When and How to Treat Inflammation.

Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
31
审稿时长
9 weeks
期刊最新文献
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action. Pathophysiology of Congestion in Heart Failure: A Contemporary Review. Imaging Advances in Heart Failure. Transcatheter Aortic Valve Replacement is Ready for Most Low-risk Patients: A Systematic Review of the Literature. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1